Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm sure they did. I was just voicing my sarcasm. Funny how they carried on for a few weeks. "Remember know what you own"
Haven't heard from jbem in awhile or the sal69 guy who was pumping this thing. Where's the $3+
From Soligenix Communications: Soligenix Audio Corporate Presentation Available
An audio of the Soligenix Corporate Presentation is available on the Company website. To listen and view the presentation, please visit www.soligenix.com.
Can't take full credit since it was emailed to me by sngx investor relations. You can sign up for email notifications.
See full publication on SNGX website....http://www.soligenix.com/publications.shtml
Drs. Schaber and Straube Discuss Treatment of
Cutaneous T-Cell Lymphoma in Recent Publication
Drs. Christopher Schaber and Richard Straube are working to change the prognosis for patients with rare and poorly treated diseases. They introduce Soligenix and its investigational drug, SGX301 (synthetic hypericin), for the treatment of cutaneous T-cell lymphoma. You can read the full article published in the July 17, 2015 edition of International Innovation at www.soligenix.com or http://www.internationalinnovation.com/new-digital-edition-issue-190-available-now/.
Interesting article from Life Science Leader.
http://www.lifescienceleader.com/component/k2/item/4540-biodefense-and-biotherapeutics-gain-federal-support
Zacks published a very detailed report yesterday on SNGX. Their 12 target price is $4.50.
Sinofresh is now being sold by HealthTech Brands, another Orlund's company. It appears he transferred/sold the product IP to this new company. I see that it was registered with the FL SOS's office on Dec. 11, 2012.
Does anyone have any additional information? I know I'm beating a dead horse here but it would be nice to know what happened.
It is excellent news! But I'm a little concerned about the S-1 filed on Monday with 7M of new shares. Dilution.
Head to the Sarasota County Court. Both Orlund and Baumgardner were subpoenaed on two cases from Charles and S. Fust. The court documents are sealed so I have no idea what the lawsuit is about.
Well I see it made it to print.
http://www.review.net/section/detail/sinus-clearing-firm-all-clogged-up-again/
They did not buy any shares. The company was nice enough to offer them options at $.30/share. Total shares for all 4 were 100k. Guess that's the only way to retain them.
I tried to email SFSH to see if they have any updates. It was returned undeliverable. Also the website is down and phone not working. Unless they didn't pay the bills, it sounds like they are officially out of business. Guess this was inevitable. Has anyone else heard anything?
Its still in the pipeline for prevention and treatment of chronic. The phase 3 study for treatment of acute is gone. Just confirms it's finished.
I see management updated the corporate presentation on June 1st. A couple things to note: Orbec - Treatment of Acute GI GVHD is no longer listed in the pipeline. Was listed as terminated on April presentation. The results for Rivax Phase 1b has been pushed to 2H 2012.
Didn't hear back from Bill as expected. Did you get anything from your contact?
I don't blame you for not cutting them slack. It's obvious the market doesn't respect them either. This stock is trading around the value of cash per share. Well less if you consider the numbers at year-end. No credit for what's being developed. Now we have to worry about dilution.
Great according to the proxy just issued, the company want to increased the number of authorized shares by 30M. Sorry for the long post, but everyone should be aware of this
Our Amended and Restated Certificate of Incorporation currently provides for 20,000,000 shares of authorized Common Stock. Our Board of Directors has adopted a resolution to approve a Second Amended and Restated Certificate of Incorporation, which increases the authorized number of shares of Common Stock to 50,000,000, subject to stockholder approval. No changes will be made to the number of authorized shares of our preferred stock.
The proposed increase in the number of shares available for issuance is intended to provide the Board of Directors with authority, without further action of the stockholders, to issue the additional shares of Common Stock, from time to time in such amounts as the Board of Directors deems necessary. Without limitation of the foregoing, the additional shares may be issued in connection with (1) capital raising transactions through the sale of Common Stock and/or securities convertible into or exercisable for Common Stock in the private and/or public equity markets to support a higher level of growth, respond to competitive pressures, develop new products and services and support new strategic partnership expenditures, and (2) strategic partnering or acquisition transactions involving the issuance of our securities as well as to meet long-term corporate objectives.
The need to increase the authorized number of shares is primarily driven by our desire to have sufficient shares available for possible merger and acquisition activities, securities offerings, and other corporate development objectives that may occur over the coming years. However, we have no present plans, arrangements or understandings with any specific entity to engage in such activities.
The proposed increase in the authorized number of shares of Common Stock could have other effects on our stockholders. The increase could deter takeovers, in that additional shares could be issued (within the limits imposed by applicable law) in one or more transactions that could make a change in control or takeover of us more difficult. For example, additional shares could be issued by us so as to dilute the stock ownership or voting rights of persons seeking to obtain control. Similarly, the issuance of additional shares to certain persons allied with our management could have the effect of making it more difficult to remove our current management by diluting the stock ownership or voting rights of persons seeking to cause such removal.
Any legal recourse for us shareholders?
I meant secures more funding.
But for someone at his level, why only invest $5,000? What signal does that really send. It feels more like a gimmick to me. I'll feel encouraged when we get some positive Phase II results and the company secures more financing. Hopefully this year!!
I would feel better if he bought more than $5000 worth of stock. And I'm surprised that he only holds 50k worth. Didn't he earn 478K as CEO last year?
Did they confirm that or did you just not hear back? I was going to try to contact the CFO. I believe his name is Bill.
Still no word from Mgmt? We've waited a long time to hear something. You would think something has happened in a year.
The company release a new corporate presentation on their website. It goes into detail about the pipeline.
My take is they have enough cash to fund a Phase II trial for Crohn's.
www.soligenix.com
Less than a year ago we were at 34 cents presplit. Now 37 cents postsplit after a 20/1. Where's the bottom?
And I stand corrected. Looks like they have recently updated it.
And then finished back down again! Mgmt has been quiet lately. We should be getting a earnings release next week and hopefully a clinical update. I've requested they update their website pipeline with recent developments.
Could you please elaborate on what you were told by mgmt?
Haven't heard an update since Bobbott met with the CFO in October. The website is still accepting orders so they are still in business. Seemed at this time last year we got a PR every week saying how the company is going be turned around.
It's not just her. The company highlighted this in their press release. We all know that Biotechs burn cash quickly. Even if they release positive news on other compounds, they still need cash for additional trials and commercialization.
Does it really look good? Currently, it’s great that the company has cash and no debt but the cash is only projected to last until 2013. They need to continue to raise $$ and they are years off from commercializing a product. They had a nice partnership with Sigma-Tau on Orbec with the milestone payments and 35% royalty. Thankfully, Sigma made an upfront payment or we would be in serious trouble.
I thought PI/II results for SGX201 - Radiation Enteritis were supposed to be published by the end of 2011. Look at the 10Q. It now says 1H 2012. What no PR on the delay?
Not since they released the shareholder FAQ on their website. That was 3 weeks ago.
The only thing left for them to do is to find a lender that will let them borrow a large amount of money against the product IP. Good luck finding one these days. If by some miracle they do it, they still have to sell a lot of nasal spray. My opinion is the product is great but maybe overpriced for some. Need two hail mary passes here. GLTA.
I guess we'll find out tomorrow. This is what happens when you believe in the management instead of doing solid DD. And how do you know I guess right on any of my points? And how do we know a PR is coming tomorrow? Stocksplit did you speak to management?
Are you suggesting that I broke into Sinofresh’s website and read tomorrow’s update? Come on. I just stated my opinions/conclusions based on the 5/25 PR, your posts as well as Stocksplit123 posts. It apparent the company has some cashflow issues so how would they complete any of the things listed on their strategic plan. Stocksplit123 conversation with management stated they had no money for the audit.
As for stock tips, I invested in Sinofresh starting in Q1 2011. How’s that for being smart? The product works very well but that’s it.